Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Breast (Edinburgh, Scotland)|February 8, 2025
Multimodal data integration in early-stage breast cancerArnau Llinas-Bertran, Maria Butjosa-Espín, Vittoria Barberi, et al.
Recenti Progressi in Medicina|June 27, 2022
Palbociclib plus letrozole induces a complete metabolic response in metastatic breast cancer patient with idiopathic thrombocytopeniaVittoria Barberi, Davide Renna, Alessio Annovazzi, et al.
Breast (Edinburgh, Scotland)|July 27, 2025
Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancerMichelle Li, François Panet, Vittoria Barberi, et al.
Frontiers in Oncology|January 30, 2023
Unusual phylogenetic tree and circulating actionable ESR1 mutations in an aggressive luminal/HER2-low breast cancer: Case reportMatteo Allegretti, Vittoria Barberi, Cristiana Ercolani, et al.
Journal of Personalized Medicine|July 2, 2021
Oligometastatic Breast Cancer: How to Manage It?Vittoria Barberi, Antonella Pietragalla, Gianluca Franceschini, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2021
The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute surveyVincenzo Di Noia, Davide Renna, Vittoria Barberi, et al.
Current Oncology Reports|February 24, 2024
An Integrated Care Approach to Improve Well-Being in Breast Cancer PatientsAlessandra Fabi, Alessandro Rossi, Edoardo Mocini, et al.
Oncology|December 7, 2021
Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice?Alessandra Fabi, Mariangela Ciccarese, Sinome Scagnoli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2021
Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single InstitutionVincenzo Di Noia, Fulvia Pimpinelli, Davide Renna, et al.
The Oncologist|November 23, 2023
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL StudyAndrea Botticelli, Roberta Caputo, Simone Scagnoli, et al.
Pageof 1